Todos os estudos
RecrutamentoFASE1INTERVENCIONISTA

Um Estudo de Fase 1a/1b de ELVN-001 para o Tratamento da Leucemia Mieloide Crônica

This study is investigating a new medication, ELVN-001, for adults living with Chronic Myeloid Leukaemia (CML). CML is a type of blood cancer. This first-stage study wants to find the safest and most effective dose of ELVN-001. Researchers will also be looking closely at any side effects and how well the medicine works, particularly for patients whose CML hasn't responded to previous treatments, or if those treatments caused difficult side effects. The goal is to understand if ELVN-001 could be a good new option for CML patients in the future, helping them achieve better results and a good quality of life.

Em resumo

Status
Recrutamento
Fase
FASE1
Patrocinador
Enliven Therapeutics
Meta de inscrição
250
Iniciar
22 May 2022
Conclusão estimada
01 Dez 2027

Sobre o que é este estudo?

This study is about a new medicine called ELVN-001, which is being tested in people with Chronic Myeloid Leukaemia (CML). CML is a slow-growing cancer of the blood and bone marrow. The main purpose of this early-stage study is to understand more about ELVN-001 – for example, what is the best dose to give, how safe it is, and if it causes any side effects. Researchers will also look at how the body handles the medicine and if it shows early signs of helping to control CML.

ELVN-001 is being developed for people with CML, especially those who haven't responded well to other common CML treatments called TKIs, or who have found the side effects of those treatments too difficult to manage. Some people with CML also have a specific change in their cancer cells (called a T315I mutation) that can make their CML harder to treat; this study includes people with and without this mutation.

The hope is that ELVN-001 could offer a new and effective treatment option. The collected information will be used to help researchers decide if ELVN-001 should be studied in larger groups of people and potentially become a new treatment available for CML patients in the future.

Pontos principais

  • This is an early-stage study for a new CML medicine called ELVN-001.
  • It's for adults with CML who haven't responded well to other treatments or had bad side effects.
  • The study aims to find the right dose, check safety, and see if it helps control CML.
  • You'll be closely monitored by a medical team.
  • A participação é voluntária, e você pode se retirar a qualquer momento.

Quem pode ser elegível?

To join this study, adult patients must have a specific type of CML called "chronic phase" CML. Your CML cells must also have a specific genetic marker called BCR-ABL1. It's okay if you also have the T315I mutation.

Importantly, your current CML treatments must not be working well for you, or you must have found them too difficult to tolerate due to side effects. For patients in the UK and other parts of the world, this means you've either tried and failed at least one other type of CML medication (specifically a 'second-generation TKI' or asciminib), or that other available treatments for your CML aren't suitable for you. You also need to be generally well enough to take part and not have certain other health issues.

There are also some reasons why you might not be able to join. For example, if you've recently had other anti-cancer treatments, or if you have a history of certain heart or pancreas problems. The study doctors will carefully check all your health details to make sure the study is safe for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você é um adulto com 18 anos ou mais?
  2. Do you have Chronic Myeloid Leukaemia (CML) in its 'chronic phase'?
  3. Has your CML not responded well to at least one previous TKI treatment, or did you have difficult side effects from it?
  4. Are you generally well and able to carry out your daily activities?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you will receive doses of the new medicine, ELVN-001. This is a "dose escalation" study, which means that different groups of people will receive carefully increasing doses of the medicine to find the safest and most effective amount. You will have regular appointments with the study team for blood tests, physical exams, and other checks to see how you are doing and how the medicine is affecting your body and your CML.

The study team will carefully monitor your health for any side effects and how well the treatment is working. This will involve closely looking at your CML cells to see if the medicine is reducing the number of cancer cells. The total length of your participation will depend on how you respond to the treatment and the study plan, but you will have ongoing support and monitoring throughout.

Riscos e benefícios potenciais

Taking part in any medical study has potential benefits and potential risks. A possible benefit is that ELVN-001 might help control your CML, especially if other treatments haven't worked well for you. It's important to remember that this is a new medicine and its full effects are still being understood. Potential risks include experiencing side effects from the medication. The study team will explain all known and possible side effects to you before you decide to join. Your safety is their top priority, and you will be carefully monitored. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (45)

  • Centro de Câncer Memorial Sloan Kettering
    Código postal verificado
    Nova Iorque, Estados Unidos· Recrutamento
  • Montefiore Medical Center
    Código postal verificado
    The Bronx, United States· Recrutamento
  • Oregon Health & Science University-Knight Cardiovascular Institute
    Código postal verificado
    Portland, Estados Unidos· Recrutamento
  • The University of Texas MD Anderson Cancer Center
    Código postal verificado
    Houston, Estados Unidos· Recrutamento
  • Royal Adelaide Hospital
    Código postal verificado
    Adelaide, Austrália· Recrutamento
  • UZ Gent
    Código postal verificado
    Gante, Bélgica· Recrutamento
  • UZ Leuven
    Código postal verificado
    Leuven, Bélgica· Recrutamento
  • CHU Liege
    Código postal verificado
    Liège, Bélgica· Recrutamento
  • University Health Network (UHN) - Princess Margaret Cancer Centre
    Código postal verificado
    Toronto, Canadá· Recrutamento
  • CHU Amiens Picardie Site Sud
    Código postal verificado
    Amiens, France· Recrutamento
  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    Código postal verificado
    Bordéus, França· Recrutamento
  • CHRU de Lille - Hopital Calmette-Boulevard du Pr Leclercq CHRU Lille
    Código postal verificado
    Lille, France· Recrutamento

Perguntas frequentes

What is CML?

CML stands for Chronic Myeloid Leukaemia. It's a type of cancer that starts in the blood-forming cells of the bone marrow.

What does 'TKI' mean?

TKI stands for Tyrosine Kinase Inhibitor. These are a common type of medicine used to treat CML.

What is a 'first-in-human' trial?

This means it's one of the first times this new medicine, ELVN-001, is being given to people. It's an important early step in testing new treatments.

Will I know if I'm getting the active drug?

Yes, in this type of study, all participants receive the active drug, ELVN-001, at different doses.

How long will my participation last?

The exact duration will depend on your individual response and the study doctor's plan, but you will be monitored throughout your time on the trial.

Como saber mais

Contato para Estudo

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic My…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.